Also, specificity increased with lower antigen coating. rate of tumor mice. Discussion In VAL-083 summary, our new anti-GPC3 nanobody suggests a strong application potential for targeted therapy of liver cancer. TG1, BL21, prokaryotic vector pET28a, and HepG2 cells from the Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, Xinjiang University (Urumqi, Xinjiang, China), Taq DNA polymerase and deoxynucleotides (dNTPs) from Takara (Dalian, China), DAB (3, 3?-diaminobenzidine), ampicillin, kanamycin sulfate, and isopropyl-D- thiogalactopyranoside (IPTG) from Solarbio Biotechnology (Beijing, China), anti-His and horseradish peroxidase (HRP)-conjugated anti-his monoclonal antibodies (mAbs) from Beyotime Biotechnology (Shanghai, China), anti-human GPC3 mAbs from ACRO Biosystems (Beijing, China), and Anti-6His fluorescein isothiocyanate (FITC) from abcam (Cambridge, UK). Camel Immunization and Ethics Statement A Bactrian camel from Xinjiang Province, China, was immunized five times with 50 mg of GPC3 fusion protein.18 All animal experiments were approved by the Committee on the Ethics of Animal Experiments of Xinjiang Key Laboratory of Biological Resources and Genetic Engineering (BRGE-AE001) and performed under the guidelines of the Animal Care and Use Committee of College of Life Science and Technology, Xinjiang University. Serum antibody titers were determined by ELISA. Phage Library Construction Total mRNA was extracted from peripheral blood VAL-083 mononuclear cells (PBMCs) using Trizol reagent and examined using agarose gel electrophoresis. cDNA was generated using M-MLV Reverse Transcriptase. Specific primers were designed based on complementary sequences to two conserved regions in the heavy-chain variable region of camel nanobody. VHH genes were then amplified by PCR in a 25-L reaction mixture containing 5 L 5 PS buffer (+Mg2+), 0.5 L dNTP, 0.25 L cDNA, 0.25 L PrimeSTAR, and 0.5 L forward primer and reverse primer. The PCR products and the pCANTAB-5E vector were digested sequentially with I and VAL-083 I, then ligated by T4 DNA ligase at 16C overnight and electro-transformed into competent TG1 cells.19 Phage Amplification and Titering The phage library (100 L) was inoculated into 50 mL of LB medium containing 50 L ampicillin at 37C and grown until log phage (OD600 = 0.5?0.6). Helper phage M13KO7 at about 5 1012 colony-forming units (cfu)/mL was then added and the mixture incubated for 1 hr at 37C. Bacteria were harvested by centrifugation for 10 mins at 2500 g and resuspended in 100 mL fresh LB medium with 100 L ampicillin. The new suspension was incubated at 37C overnight. The next day, bacterial cells were removed by centrifugation for 20 mins at 2500 g and phages were precipitated from the supernatant with 1/5 volume 20% polyethylene glycol(PEG)-NaCl 8000. The precipitated phages were resuspended in phosphate-buffered saline (PBS) for titer measurement and the next round of bio-panning. For titering, the phage solutions were diluted 1:10, 1:100, and 1:1000 in fresh LB medium. Serial dilutions of phage (100 L) were added to 900 L TG1 cells and the mixture incubated for Rabbit Polyclonal to GPR17 30 mins at 37C. Then, a 100 L volume of this cell suspension was coated onto solid LB culture medium and incubated at 30C overnight. The colonies were counted and phage titer calculated as plaque-forming units (pfu).20,21 Screening of Special VHH Against GPC3 GPC3 protein in carbonate buffer [pH 9.6] (1, 5, or 10 g/mL) was used to coat 96-well plates. Briefly, wells were filled with.